Search
Filter Results
Displaying 221–230 of 831 for “retinal diseases”
-
Jul 1, 2016
At VISIONS 2016, FFB’s national conference, the Foundation honored him with its Ed Gollob Board of Directors Award for breakthrough research conducted within the past year.
-
Mar 20, 2014
UCI Stem-Cell Pioneer Poised to Launch Clinical Trial for RP Patients
Dr. Henry Klassen’s progenitor-based therapy has the potential to rescue a variety of retinal cells — including rods, cones, retinal pigment epithelium and ganglion cells — and, therefore, may save vision in people with a wide range of conditions.
-
Sep 6, 2023
Therapeutic Targets for Dry AMD: A Foundation Fighting Blindness Webinar for Eye Care Professionals
The free, online event will feature a lecture from David Boyer, MD, a Senior Partner at Retina-Vitreous Associates Medical Group and dry AMD expert.
-
Investing in Cures Summit 2021
The 2021 Investing in Cures Summit (ICS) convenes key stakeholders of the Foundation Fighting Blindness and RD Fund to learn from the world’s leading industry, clinical and retinal science innovators poised to take emerging therapies across the finish line.
-
Apr 9, 2021
Foundation Invests $5.5 Million in Seven New Translational Research Projects
Projects target a variety of conditions including: age-related macular degeneration, Stargardt disease, retinitis pigmentosa, and Usher syndrome type 3A
-
Aug 3, 2020
With a founding investment from Hatteras Venture Partners, Atsena has raised a total of $8.15 million for its launch.
-
May 19, 2015
ARVO 2015 Highlight: The National Eye Institute Invests $4 Million in Audacious-Goals Research
The mission of the program—to regenerate the neurons and neural connections in the eye and visual system—is synonymous with the Foundation’s mission to eradicate retinal diseases.
-
Nov 8, 2023
Kiora Reports Vision Restoration in Phase 1/2 Clinical Trial for Photoswitch Therapy
The company’s molecule is designed to restore some vision to people with ultra-low or no vision caused by advanced retinitis pigmentosa and other retinal diseases.
-
Jan 6, 2022
RD Fund Announces Series B Financing Behind SalioGen Therapeutics
Investment in new portfolio company furthering genetic medicine approaches for individuals affected by retinal degenerative diseases.
-
Nov 27, 2019
Known as Pro-EYS, the study will help researchers design clinical trials for potential therapies